IGC Pharma (FRA:IGS1) Gross Margin % : 65.24% (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is IGC Pharma Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. IGC Pharma's Gross Profit for the three months ended in Dec. 2023 was €0.12 Mil. IGC Pharma's Revenue for the three months ended in Dec. 2023 was €0.19 Mil. Therefore, IGC Pharma's Gross Margin % for the quarter that ended in Dec. 2023 was 65.24%.

The historical rank and industry rank for IGC Pharma's Gross Margin % or its related term are showing as below:

FRA:IGS1' s Gross Margin % Range Over the Past 10 Years
Min: 2.58 Med: 12.91 Max: 51.4
Current: 51.4

During the past 13 years, the highest Gross Margin % of IGC Pharma was 51.40%. The lowest was 2.58%. And the median was 12.91%.

FRA:IGS1's Gross Margin % is ranked worse than
59.87% of 750 companies
in the Biotechnology industry
Industry Median: 60.53 vs FRA:IGS1: 51.40

IGC Pharma had a gross margin of 65.24% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for IGC Pharma was 93.70% per year.

IGC Pharma Gross Margin % Historical Data

The historical data trend for IGC Pharma's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGC Pharma Gross Margin % Chart

IGC Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Gross Margin %

Get a 7-Day Free Trial

2.58

2.82

12.60

48.89

48.53

IGC Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Margin %	Get a 7-Day Free Trial															30.67	38.06	45.90	59.71	65.24

Competitive Comparison of IGC Pharma's Gross Margin %

For the Biotechnology subindustry, IGC Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IGC Pharma's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGC Pharma's Gross Margin % distribution charts can be found below:

* The bar in red indicates where IGC Pharma's Gross Margin % falls into.

IGC Pharma Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

IGC Pharma's Gross Margin for the fiscal year that ended in Mar. 2023 is calculated as

Gross Margin % (A: Mar. 2023 )	=	Gross Profit (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	0.4	/	0.851
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(0.851 - 0.438)	/	0.851
	=	48.53 %

IGC Pharma's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	0.1	/	0.187
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(0.187 - 0.065)	/	0.187
	=	65.24 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

IGC Pharma (FRA:IGS1) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

IGC Pharma had a gross margin of 65.24% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

IGC Pharma Gross Margin % Related Terms

Thank you for viewing the detailed overview of IGC Pharma's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

IGC Pharma (FRA:IGS1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGC Pharma Inc (FRA:IGS1) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

IGC:USA

Address

10224 Falls Road, Potomac, MD, USA, 20854

Website

https://www.igcinc.us

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

IGC Pharma (FRA:IGS1) Headlines

No Headlines